# Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

> **NCT01504776** · PHASE1 · COMPLETED · sponsor: **Anand Jillella** · enrollment: 3 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01504776
- **Lead sponsor:** Anand Jillella
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2014-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01504776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01504776, "Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01504776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*